Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai

Microbial Chemistry Research Foundation

Other

Kanegafuchi Kagaku Kogyo Kabushiki Kaisha

Bristol-myers Company

Hokko Chemical Industry Co., Ltd.

Sanraku Incorporated

501 Azidan Hojin Biseibutsu Kagaku Kenkyu Kai

Hiroshi Naganawa

Tomio Takeuchi

Masa Hamada

Hamao Umezawa

Masaaki Ishizuka

Toshikazu Oki

Taiji Inui

Hironobu Iinuma

Takaaki Aoyagi

Yasuhiko Muraoka

Tsutomu Sawa

Shinichi Kondo

Yoshikazu Takahashi

Kenji Maeda

Kunio Isshiki

Kuniaki Tatsuta

Norio Shibamoto

Masaya Imoto

Takeshi Uchida

Nobuyoshi Shimada

Tomohisa Takita

Masayuki Igarashi

Makoto Tsuda

Keiji Ogawa

Machiko Nagai

Setsuko Kunimoto

Tomoyuki Ishikura

Masatoshi Abe

Hideki Hashizume

Rokuro Okamoto

Akihiro Yoshimoto

Munekazu Iinuma

Yusuke Wataya

Hye-Sook Kim

Kazuo Umezawa

Yoko Ikeda

Yoshio Watanabe

Hiroyuki Kumagai

Osamu Jodo

Tetsuo Akiyama

Kiyoshi Sato

Shigemi Yoshida

Takayuki Aoyama

Takashi Yamashita

Mitsuhiro Ueno

Hiroomi Watabe

Masaaki, All Ishizuka

Takaaki Nishikiori

By culturingsp. BMK333-48F3 (deposit number of FERM BP-7477), an antibiotic, tripropeptin Z, tripropeptin A, tripropeptin B, tripropeptin C or tripropeptin D represented by the general formula (I): wherein R is 7-methyl-octyl group, 8-methyl-nonyl group, 9-methyl-dodecyl group, 10-methyl-undecyl group or 11-methyl-dodecyl group, is obtained as antibiotics having excellent antibacterial activities against bacteria and having a novel molecular structure. These tripropeptins each have an excellent antibacterial activity against various bacteria and drug-resistant strains thereof, such as methicillin-resistant strains and vancomycin-resistant strains.

Antibiotics, tripropeptins and process for producing the same

An antibiotic SF2487 substance having the formula (I)or a salt thereof possesses an antimalarial activity against the proliferation of malarial parasites and is therefore useful as an antimalarial drug.

Compositions for treating or preventing malaria and method of treating malaria

Antibiotic caprazamycins and process for producing the same

As novel substances having an activity of inducing an apoptosis even on the apoptosis-resistant cancer cells, there are obtained polyoxypeptin and deoxypolyoxypeptin represented by the following general formula (I)

Physiologically active polyoxypeptin and deoxypolyoxypeptin and anticancer drugs containing the same

This invention provides a physiologically active substance having a strong dipeptidyl peptidase IV inhibitory activity. The physiologically active substance sulphostin is obtained by culturing a microorganism belonging to the genus Streptomyces and having an ability to produce the physiologically active substance sulphostin, producing and accumulating this substance in the cultures, and harvesting it from the cultures.

Physiologically active substance sulphostin, process for producing the same, and use thereof

Antibiotics having immunosuppressive activity, delaminomycins and

A novel, biologically active substance, poststatin, has been isolated from a culture medium of microorganism belonging to Streptomyces. The novel substance is a peptide compound having a novel structure, wherein the peptide chains have ketone radicals. Thus substance has a high endopeptidase inhibition activity. It is possible to chemically synthesize poststatin related compound having ketone radicals in the peptide chains. These compounds also have an endopeptidase inhibition activity.

Poststatin and related compounds or salts thereof

Polyether antibiotic MI215-NF3 substance, production process thereof,

Benastatins A and B which are novel and physiologically active substances having the formula ##STR1## wherein R represents --CH.sub.2 --CH.sub.2 -- or --CH.dbd.CH--, exhibit a potent immunomodifier activity, a glutathione transferase inhibition activity and an anti-microorganism activity and are therefore extremely useful for various drugs.

Physiologically active substances, benastatins A and B, and production

A new antibiotic, named Conagenin, is provided which can exhibit useful carcinostatic or antitumor activities on carcinomas and tumors, particularly malignant tumors, of mammalian animals including man. Conagenin can be produced by fermentation of microorganisms of genus Streptomyces, typically Streptomyces roseosporus MI696-AF3 strain identified under the deposit number FERM BP-2738. Conagenin has formula (I) and is useful for medicinal purposes, particularly as carcinostatic agent or antitumor agent for inhibiting carcinomas and malignant tumors of mammalian animals, including man.

Carcinostatic or antitumor antibiotic, conagenin, and production and

As a new antibiotic is provided a compound, now nominated as MI43-37F11 substance, which has formula ##STR1## This MI43-37F11 substance has an antitumor activity, an activity to enhance the production of interleukin-1 in vivo in a mammalian, and an activity to activate a macrophage in vivo in a mammalian. MI43-37F11 substance may be produced by cultivation of Streptoverticillium eurocidicum MI43-37F11 strain identified as FERM BP-2783.

Anticancer antibiotic MI43-37F11 substance

New physiologically active substances, named probestin and prostatin, respectively, are produced from a new microorganism, Streptomyces azureus MH663-2F6 strain identified as FERM P-9541 or FERM BP-1963. Probestin and prostatin have an activity inhibitory to aminopeptidase M and also have immunopotentiating properties.

Physiologically active substances, probestin and prostatin and

Disclosed are anthracycline antibiotics of a formula (I): ##STR1## in which R.sup.1 and R.sup.2 are hydroxyl groups, R.sup.3 is ethyl group, R.sup.4 is methoxycarbonyl group and X represents daunosamine-rhodenose or daunosamine-deoxyfucose; or

Anthracycline antibiotics

Plipastatin represented by the general formula ##STR1## wherein R.sub.1 is --C.sub.13 H.sub.27 or --C.sub.14 H.sub.29 ; and R.sub.2 is Ala or Val, or salts thereof, which is prepared by culturing a Plipastatin-producing strain belonging to the genus Bacillus to produce and accumulate Plipastatin in a cultured broth and then isolating Plipastatin from the cultured broth. Plipastatin exhibits an enzyme inhibiting activity against phospholipase A.sub.2, C and D and which will be useful as an immunosuppressive agent or as a type I anti-allergic agent.

Plipastatin and method for preparation thereof

Growing community of inventors

Tokyo, Japan

Hiroshi Naganawa